AB ANALITICA
Private Company
Funding information not available
Overview
AB ANALITICA is a commercial-stage, private diagnostics company with a 30-year legacy in molecular diagnostics, operating from Padua, Italy. The company develops and markets a broad portfolio of IVD products, including kits for infectious disease (e.g., fungal, antibiotic resistance), genetic testing (e.g., CFTR, exome sequencing), and automated instruments like the GENEQUALITY 2050 system. It leverages a multi-platform strategy combining molecular and immunoassay technologies and drives growth through strategic distribution partnerships (e.g., with SNIBE, USTAR) and a focus on high-growth areas like NGS and automation.
Technology Platform
Multi-platform diagnostics company with technologies in Real-Time PCR, Next-Generation Sequencing (NGS) library prep, Reverse Line Blot, fully integrated PCR automation, and Immunoassays (ELISA/CLIA).
Opportunities
Risk Factors
Competitive Landscape
AB ANALITICA competes in a crowded market dominated by multinational giants like Roche, Abbott, bioMérieux, and Thermo Fisher. It differentiates through niche expertise in specific infectious disease and genetic tests, a fully integrated automation system, and agility as a private, focused player. Its partnerships help it compete in segments like immunoassay and POC.